CTOs on the Move

Daily.co

www.daily.co

 
Hello! We`re Daily, the developer platform for real-time video. Our APIs let developers add video calls to any app or site.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.daily.co
  • 1231 9th Ave
    San Francisco, CA USA 94116
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Daily.co raised $15M on 03/09/2021
Daily.co raised $40M on 11/10/2021

Similar Companies

Hologra

Hologra is a Cave Creek, AZ-based company in the Software and Internet sector.

Keynote DeviceAnywhere

Keynote DeviceAnywhere is a San Mateo, CA-based company in the Software and Internet sector.

Sekady Capital

Sekady is connecting construction through technology! We work with valued partners such as Title Companies, Fund Control Companies, Lenders, and Builders to provide centralized visibility into construction projects. Our goal is to create easy-to-use, yet innovative software solutions to arm everyone in the construction industry with the tools they need to build more efficiently, have greater visibility, and be more profitable.

AQEOS digital

In 1995, our founder, an Information Technology Systems Engineer, founded zone Technologies, an Outsourced IT Management firm in response to the growing demand for Small Businesses Class IT Services. Initially catering to small businesses and private c...

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.